Request Sample Inquiry
Asthma and Copd Drugs Market

Asthma and COPD Drugs Market

Asthma and COPD Drugs Market - Global Industry Assessment & Forecast

Number Of Pages # Pages:

199

Base Year:

2023

Date

Apr - 2024

Format:

PDF XLS PPT

Report Code:

VMR-2464

Segments Covered
  • By Diseases By Diseases Asthma, COPD
  • By Medication Class By Medication Class Combination Drugs, Bronchodilators, Inhaled Corticosteroids (ICS), Short Acting Beta Agonists (SABA), Long Acting Beta Agonists (LABA), Leukotriene Antagonists (LTA), Anticholinergics, Anti-Inflammatories, Other Classes
  • By Distribution Channel By Distribution Channel Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, Drug Stores
  • By Region By Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Snapshot
Base YearBase Year: 2023
Forecast YearsForecast Years: 2024 - 2032
Historical YearsHistorical Years: 2018 - 2022
Revenue 2023Revenue 2023: USD 37.42 Billion
Revenue 2032Revenue 2032: USD 57.56 Billion
Revenue CAGRRevenue CAGR (2024 - 2032): 4.9%
Fastest Growing Region Fastest Growing Region (2024 - 2032) Europe
Largest Region Largest Region (2023): North America
Customization Offered
  • Cross-segment Market Size and Analysis for Mentioned Segments Cross-segment Market Size and Analysis for Mentioned Segments
  • Additional Company Profiles (Upto 5 With No Cost) Additional Company Profiles (Upto 5 With No Cost)
  • Additional Countries (Apart From Mentioned Countries) Additional Countries (Apart From Mentioned Countries)
  • Country/Region-specific Report Country/Region-specific Report
  • Go To Market Strategy Go To Market Strategy
  • Region Specific Market Dynamics Region Specific Market Dynamics
  • Region Level Market Share Region Level Market Share
  • Import Export Analysis Import Export Analysis
  • Production Analysis Production Analysis
  • Other Others Request Customization Speak To Analyst
  1. Executive Dashboard
    1. Strategic Imperatives
  2. Premium Insights
    1. Top 3 Trends to Watch
    2. Demand and Supply Trends
    3. Top 3 Strategies Followed by Major Players
    4. Top 3 Predictions by Vantage Market Research
    5. Top Investment Pockets
    6. Insights from Primary Respondents
  3. Global Asthma and COPD Drugs Market - Segment Analysis
    1. Overview
    2. Global Asthma and COPD Drugs Market, 2016 - 2028 (USD Million)
    3. Global Asthma and COPD Drugs Market - by Diseases
      1. By Asthma
      2. By COPD
    4. Global Asthma and COPD Drugs Market - by Medication Class
      1. By Combination Drugs
      2. By Bronchodilators
      3. By Inhaled Corticosteroids (ICS)
      4. By Short Acting Beta Agonists (SABA)
      5. By Long Acting Beta Agonists (LABA)
      6. By Leukotriene Antagonists (LTA)
      7. By Anticholinergics
      8. By Anti-Inflammatories
      9. By Other Classes
    5. Global Asthma and COPD Drugs Market - by Distribution Channel
      1. By Retail Pharmacies
      2. By Hospital Pharmacies
      3. By Online Pharmacies
      4. By Drug Stores
    6. Global Asthma and COPD Drugs Market - by region
      1. North America
      2. Europe
      3. Asia Pacific
      4. Latin America
      5. Middle East & Africa
    7. Market comparative analysis
  4. North America Asthma and COPD Drugs Market - Segment Analysis
    1. Overview
    2. North America Asthma and COPD Drugs Market, 2016 - 2028 (USD Million)
    3. North America Asthma and COPD Drugs Market, by Diseases
      1. By Asthma
      2. By COPD
    4. North America Asthma and COPD Drugs Market, by Medication Class
      1. By Combination Drugs
      2. By Bronchodilators
      3. By Inhaled Corticosteroids (ICS)
      4. By Short Acting Beta Agonists (SABA)
      5. By Long Acting Beta Agonists (LABA)
      6. By Leukotriene Antagonists (LTA)
      7. By Anticholinergics
      8. By Anti-Inflammatories
      9. By Other Classes
    5. North America Asthma and COPD Drugs Market, by Distribution Channel
      1. By Retail Pharmacies
      2. By Hospital Pharmacies
      3. By Online Pharmacies
      4. By Drug Stores
    6. North America Asthma and COPD Drugs Market, by Country
      1. U.S.
        1. U.S. Asthma and COPD Drugs Market, By Diseases
          1. By Asthma
          2. By COPD
        2. U.S. Asthma and COPD Drugs Market, By Medication Class
          1. By Combination Drugs
          2. By Bronchodilators
          3. By Inhaled Corticosteroids (ICS)
          4. By Short Acting Beta Agonists (SABA)
          5. By Long Acting Beta Agonists (LABA)
          6. By Leukotriene Antagonists (LTA)
          7. By Anticholinergics
          8. By Anti-Inflammatories
          9. By Other Classes
        3. U.S. Asthma and COPD Drugs Market, By Distribution Channel
          1. By Retail Pharmacies
          2. By Hospital Pharmacies
          3. By Online Pharmacies
          4. By Drug Stores
      2. Canada
        1. Canada Asthma and COPD Drugs Market, By Diseases
          1. By Asthma
          2. By COPD
        2. Canada Asthma and COPD Drugs Market, By Medication Class
          1. By Combination Drugs
          2. By Bronchodilators
          3. By Inhaled Corticosteroids (ICS)
          4. By Short Acting Beta Agonists (SABA)
          5. By Long Acting Beta Agonists (LABA)
          6. By Leukotriene Antagonists (LTA)
          7. By Anticholinergics
          8. By Anti-Inflammatories
          9. By Other Classes
        3. Canada Asthma and COPD Drugs Market, By Distribution Channel
          1. By Retail Pharmacies
          2. By Hospital Pharmacies
          3. By Online Pharmacies
          4. By Drug Stores
      3. Mexico
        1. Mexico Asthma and COPD Drugs Market, By Diseases
          1. By Asthma
          2. By COPD
        2. Mexico Asthma and COPD Drugs Market, By Medication Class
          1. By Combination Drugs
          2. By Bronchodilators
          3. By Inhaled Corticosteroids (ICS)
          4. By Short Acting Beta Agonists (SABA)
          5. By Long Acting Beta Agonists (LABA)
          6. By Leukotriene Antagonists (LTA)
          7. By Anticholinergics
          8. By Anti-Inflammatories
          9. By Other Classes
        3. Mexico Asthma and COPD Drugs Market, By Distribution Channel
          1. By Retail Pharmacies
          2. By Hospital Pharmacies
          3. By Online Pharmacies
          4. By Drug Stores
  5. Europe Asthma and COPD Drugs Market - Segment Analysis
    1. Overview
    2. Europe Asthma and COPD Drugs Market, 2016 - 2028 (USD Million)
    3. Europe Asthma and COPD Drugs Market, by Diseases
      1. By Asthma
      2. By COPD
    4. Europe Asthma and COPD Drugs Market, by Medication Class
      1. By Combination Drugs
      2. By Bronchodilators
      3. By Inhaled Corticosteroids (ICS)
      4. By Short Acting Beta Agonists (SABA)
      5. By Long Acting Beta Agonists (LABA)
      6. By Leukotriene Antagonists (LTA)
      7. By Anticholinergics
      8. By Anti-Inflammatories
      9. By Other Classes
    5. Europe Asthma and COPD Drugs Market, by Distribution Channel
      1. By Retail Pharmacies
      2. By Hospital Pharmacies
      3. By Online Pharmacies
      4. By Drug Stores
    6. Europe Asthma and COPD Drugs Market, by Country
      1. Germany
        1. Germany Asthma and COPD Drugs Market, By Diseases
          1. By Asthma
          2. By COPD
        2. Germany Asthma and COPD Drugs Market, By Medication Class
          1. By Combination Drugs
          2. By Bronchodilators
          3. By Inhaled Corticosteroids (ICS)
          4. By Short Acting Beta Agonists (SABA)
          5. By Long Acting Beta Agonists (LABA)
          6. By Leukotriene Antagonists (LTA)
          7. By Anticholinergics
          8. By Anti-Inflammatories
          9. By Other Classes
        3. Germany Asthma and COPD Drugs Market, By Distribution Channel
          1. By Retail Pharmacies
          2. By Hospital Pharmacies
          3. By Online Pharmacies
          4. By Drug Stores
      2. UK
        1. UK Market, By Diseases
          1. By Asthma
          2. By COPD
        2. UK Market, By Medication Class
          1. By Combination Drugs
          2. By Bronchodilators
          3. By Inhaled Corticosteroids (ICS)
          4. By Short Acting Beta Agonists (SABA)
          5. By Long Acting Beta Agonists (LABA)
          6. By Leukotriene Antagonists (LTA)
          7. By Anticholinergics
          8. By Anti-Inflammatories
          9. By Other Classes
        3. UK Market, By Distribution Channel
          1. By Retail Pharmacies
          2. By Hospital Pharmacies
          3. By Online Pharmacies
          4. By Drug Stores
      3. France
        1. France Asthma and COPD Drugs Market, By Diseases
          1. By Asthma
          2. By COPD
        2. France Asthma and COPD Drugs Market, By Medication Class
          1. By Combination Drugs
          2. By Bronchodilators
          3. By Inhaled Corticosteroids (ICS)
          4. By Short Acting Beta Agonists (SABA)
          5. By Long Acting Beta Agonists (LABA)
          6. By Leukotriene Antagonists (LTA)
          7. By Anticholinergics
          8. By Anti-Inflammatories
          9. By Other Classes
        3. France Asthma and COPD Drugs Market, By Distribution Channel
          1. By Retail Pharmacies
          2. By Hospital Pharmacies
          3. By Online Pharmacies
          4. By Drug Stores
      4. Spain
        1. Spain Asthma and COPD Drugs Market, By Diseases
          1. By Asthma
          2. By COPD
        2. Spain Asthma and COPD Drugs Market, By Medication Class
          1. By Combination Drugs
          2. By Bronchodilators
          3. By Inhaled Corticosteroids (ICS)
          4. By Short Acting Beta Agonists (SABA)
          5. By Long Acting Beta Agonists (LABA)
          6. By Leukotriene Antagonists (LTA)
          7. By Anticholinergics
          8. By Anti-Inflammatories
          9. By Other Classes
        3. Spain Asthma and COPD Drugs Market, By Distribution Channel
          1. By Retail Pharmacies
          2. By Hospital Pharmacies
          3. By Online Pharmacies
          4. By Drug Stores
      5. Italy
        1. Italy Asthma and COPD Drugs Market, By Diseases
          1. By Asthma
          2. By COPD
        2. Italy Asthma and COPD Drugs Market, By Medication Class
          1. By Combination Drugs
          2. By Bronchodilators
          3. By Inhaled Corticosteroids (ICS)
          4. By Short Acting Beta Agonists (SABA)
          5. By Long Acting Beta Agonists (LABA)
          6. By Leukotriene Antagonists (LTA)
          7. By Anticholinergics
          8. By Anti-Inflammatories
          9. By Other Classes
        3. Italy Asthma and COPD Drugs Market, By Distribution Channel
          1. By Retail Pharmacies
          2. By Hospital Pharmacies
          3. By Online Pharmacies
          4. By Drug Stores
      6. BENELUX
        1. BENELUX Asthma and COPD Drugs Market, By Diseases
          1. By Asthma
          2. By COPD
        2. BENELUX Asthma and COPD Drugs Market, By Medication Class
          1. By Combination Drugs
          2. By Bronchodilators
          3. By Inhaled Corticosteroids (ICS)
          4. By Short Acting Beta Agonists (SABA)
          5. By Long Acting Beta Agonists (LABA)
          6. By Leukotriene Antagonists (LTA)
          7. By Anticholinergics
          8. By Anti-Inflammatories
          9. By Other Classes
        3. BENELUX Asthma and COPD Drugs Market, By Distribution Channel
          1. By Retail Pharmacies
          2. By Hospital Pharmacies
          3. By Online Pharmacies
          4. By Drug Stores
      7. Rest of Europe
        1. Rest Of Europe Asthma and COPD Drugs Market, By Diseases
          1. By Asthma
          2. By COPD
        2. Rest Of Europe Asthma and COPD Drugs Market, By Medication Class
          1. By Combination Drugs
          2. By Bronchodilators
          3. By Inhaled Corticosteroids (ICS)
          4. By Short Acting Beta Agonists (SABA)
          5. By Long Acting Beta Agonists (LABA)
          6. By Leukotriene Antagonists (LTA)
          7. By Anticholinergics
          8. By Anti-Inflammatories
          9. By Other Classes
        3. Rest Of Europe Asthma and COPD Drugs Market, By Distribution Channel
          1. By Retail Pharmacies
          2. By Hospital Pharmacies
          3. By Online Pharmacies
          4. By Drug Stores
  6. Asia Pacific Asthma and COPD Drugs Market - Segment Analysis
    1. Overview
    2. Asia Pacific Asthma and COPD Drugs Market, 2016 - 2028 (USD Million)
    3. Asia Pacific Asthma and COPD Drugs Market, by Diseases
      1. By Asthma
      2. By COPD
    4. Asia Pacific Asthma and COPD Drugs Market, by Medication Class
      1. By Combination Drugs
      2. By Bronchodilators
      3. By Inhaled Corticosteroids (ICS)
      4. By Short Acting Beta Agonists (SABA)
      5. By Long Acting Beta Agonists (LABA)
      6. By Leukotriene Antagonists (LTA)
      7. By Anticholinergics
      8. By Anti-Inflammatories
      9. By Other Classes
    5. Asia Pacific Asthma and COPD Drugs Market, by Distribution Channel
      1. By Retail Pharmacies
      2. By Hospital Pharmacies
      3. By Online Pharmacies
      4. By Drug Stores
    6. Asia Pacific Asthma and COPD Drugs Market, by Country
      1. China
        1. China Asthma and COPD Drugs Market, By Diseases
          1. By Asthma
          2. By COPD
        2. China Asthma and COPD Drugs Market, By Medication Class
          1. By Combination Drugs
          2. By Bronchodilators
          3. By Inhaled Corticosteroids (ICS)
          4. By Short Acting Beta Agonists (SABA)
          5. By Long Acting Beta Agonists (LABA)
          6. By Leukotriene Antagonists (LTA)
          7. By Anticholinergics
          8. By Anti-Inflammatories
          9. By Other Classes
        3. China Asthma and COPD Drugs Market, By Distribution Channel
          1. By Retail Pharmacies
          2. By Hospital Pharmacies
          3. By Online Pharmacies
          4. By Drug Stores
      2. Japan
        1. Japan Asthma and COPD Drugs Market, By Diseases
          1. By Asthma
          2. By COPD
        2. Japan Asthma and COPD Drugs Market, By Medication Class
          1. By Combination Drugs
          2. By Bronchodilators
          3. By Inhaled Corticosteroids (ICS)
          4. By Short Acting Beta Agonists (SABA)
          5. By Long Acting Beta Agonists (LABA)
          6. By Leukotriene Antagonists (LTA)
          7. By Anticholinergics
          8. By Anti-Inflammatories
          9. By Other Classes
        3. Japan Asthma and COPD Drugs Market, By Distribution Channel
          1. By Retail Pharmacies
          2. By Hospital Pharmacies
          3. By Online Pharmacies
          4. By Drug Stores
      3. India
        1. India Asthma and COPD Drugs Market, By Diseases
          1. By Asthma
          2. By COPD
        2. India Asthma and COPD Drugs Market, By Medication Class
          1. By Combination Drugs
          2. By Bronchodilators
          3. By Inhaled Corticosteroids (ICS)
          4. By Short Acting Beta Agonists (SABA)
          5. By Long Acting Beta Agonists (LABA)
          6. By Leukotriene Antagonists (LTA)
          7. By Anticholinergics
          8. By Anti-Inflammatories
          9. By Other Classes
        3. India Asthma and COPD Drugs Market, By Distribution Channel
          1. By Retail Pharmacies
          2. By Hospital Pharmacies
          3. By Online Pharmacies
          4. By Drug Stores
      4. South Korea
        1. South Korea Asthma and COPD Drugs Market, By Diseases
          1. By Asthma
          2. By COPD
        2. South Korea Asthma and COPD Drugs Market, By Medication Class
          1. By Combination Drugs
          2. By Bronchodilators
          3. By Inhaled Corticosteroids (ICS)
          4. By Short Acting Beta Agonists (SABA)
          5. By Long Acting Beta Agonists (LABA)
          6. By Leukotriene Antagonists (LTA)
          7. By Anticholinergics
          8. By Anti-Inflammatories
          9. By Other Classes
        3. South Korea Asthma and COPD Drugs Market, By Distribution Channel
          1. By Retail Pharmacies
          2. By Hospital Pharmacies
          3. By Online Pharmacies
          4. By Drug Stores
      5. South East Asia
        1. South East Asia Asthma and COPD Drugs Market, By Diseases
          1. By Asthma
          2. By COPD
        2. South East Asia Asthma and COPD Drugs Market, By Medication Class
          1. By Combination Drugs
          2. By Bronchodilators
          3. By Inhaled Corticosteroids (ICS)
          4. By Short Acting Beta Agonists (SABA)
          5. By Long Acting Beta Agonists (LABA)
          6. By Leukotriene Antagonists (LTA)
          7. By Anticholinergics
          8. By Anti-Inflammatories
          9. By Other Classes
        3. South East Asia Asthma and COPD Drugs Market, By Distribution Channel
          1. By Retail Pharmacies
          2. By Hospital Pharmacies
          3. By Online Pharmacies
          4. By Drug Stores
      6. Rest of Asia Pacific
        1. Rest of Asia Pacific Asthma and COPD Drugs Market, By Diseases
          1. By Asthma
          2. By COPD
        2. Rest of Asia Pacific Asthma and COPD Drugs Market, By Medication Class
          1. By Combination Drugs
          2. By Bronchodilators
          3. By Inhaled Corticosteroids (ICS)
          4. By Short Acting Beta Agonists (SABA)
          5. By Long Acting Beta Agonists (LABA)
          6. By Leukotriene Antagonists (LTA)
          7. By Anticholinergics
          8. By Anti-Inflammatories
          9. By Other Classes
        3. Rest of Asia Pacific Asthma and COPD Drugs Market, By Distribution Channel
          1. By Retail Pharmacies
          2. By Hospital Pharmacies
          3. By Online Pharmacies
          4. By Drug Stores
  7. Latin America Asthma and COPD Drugs Market - Segment Analysis
    1. Overview
    2. Latin America Asthma and COPD Drugs Market, 2016 - 2028 (USD Million)
    3. Latin America Asthma and COPD Drugs Market, by Diseases
      1. By Asthma
      2. By COPD
    4. Latin America Asthma and COPD Drugs Market, by Medication Class
      1. By Combination Drugs
      2. By Bronchodilators
      3. By Inhaled Corticosteroids (ICS)
      4. By Short Acting Beta Agonists (SABA)
      5. By Long Acting Beta Agonists (LABA)
      6. By Leukotriene Antagonists (LTA)
      7. By Anticholinergics
      8. By Anti-Inflammatories
      9. By Other Classes
    5. Latin America Asthma and COPD Drugs Market, by Distribution Channel
      1. By Retail Pharmacies
      2. By Hospital Pharmacies
      3. By Online Pharmacies
      4. By Drug Stores
    6. Latin America Asthma and COPD Drugs Market, by Country
      1. Brazil
        1. Brazil Asthma and COPD Drugs Market, By Diseases
          1. By Asthma
          2. By COPD
        2. Brazil Asthma and COPD Drugs Market, By Medication Class
          1. By Combination Drugs
          2. By Bronchodilators
          3. By Inhaled Corticosteroids (ICS)
          4. By Short Acting Beta Agonists (SABA)
          5. By Long Acting Beta Agonists (LABA)
          6. By Leukotriene Antagonists (LTA)
          7. By Anticholinergics
          8. By Anti-Inflammatories
          9. By Other Classes
        3. Brazil Asthma and COPD Drugs Market, By Distribution Channel
          1. By Retail Pharmacies
          2. By Hospital Pharmacies
          3. By Online Pharmacies
          4. By Drug Stores
      2. Argentina
        1. Argentina Asthma and COPD Drugs Market, By Diseases
          1. By Asthma
          2. By COPD
        2. Argentina Asthma and COPD Drugs Market, By Medication Class
          1. By Combination Drugs
          2. By Bronchodilators
          3. By Inhaled Corticosteroids (ICS)
          4. By Short Acting Beta Agonists (SABA)
          5. By Long Acting Beta Agonists (LABA)
          6. By Leukotriene Antagonists (LTA)
          7. By Anticholinergics
          8. By Anti-Inflammatories
          9. By Other Classes
        3. Argentina Asthma and COPD Drugs Market, By Distribution Channel
          1. By Retail Pharmacies
          2. By Hospital Pharmacies
          3. By Online Pharmacies
          4. By Drug Stores
      3. Rest of Latin America
        1. Rest of Latin America Asthma and COPD Drugs Market, By Diseases
          1. By Asthma
          2. By COPD
        2. Rest of Latin America Asthma and COPD Drugs Market, By Medication Class
          1. By Combination Drugs
          2. By Bronchodilators
          3. By Inhaled Corticosteroids (ICS)
          4. By Short Acting Beta Agonists (SABA)
          5. By Long Acting Beta Agonists (LABA)
          6. By Leukotriene Antagonists (LTA)
          7. By Anticholinergics
          8. By Anti-Inflammatories
          9. By Other Classes
        3. Rest of Latin America Asthma and COPD Drugs Market, By Distribution Channel
          1. By Retail Pharmacies
          2. By Hospital Pharmacies
          3. By Online Pharmacies
          4. By Drug Stores
  8. Middle East & Africa Asthma and COPD Drugs Market - Segment Analysis
    1. Overview
    2. Middle East & Africa Asthma and COPD Drugs Market, 2016 - 2028 (USD Million)
    3. Middle East & Africa Asthma and COPD Drugs Market, by Diseases
      1. By Asthma
      2. By COPD
    4. Middle East & Africa Asthma and COPD Drugs Market, by Medication Class
      1. By Combination Drugs
      2. By Bronchodilators
      3. By Inhaled Corticosteroids (ICS)
      4. By Short Acting Beta Agonists (SABA)
      5. By Long Acting Beta Agonists (LABA)
      6. By Leukotriene Antagonists (LTA)
      7. By Anticholinergics
      8. By Anti-Inflammatories
      9. By Other Classes
    5. Middle East & Africa Asthma and COPD Drugs Market, by Distribution Channel
      1. By Retail Pharmacies
      2. By Hospital Pharmacies
      3. By Online Pharmacies
      4. By Drug Stores
    6. Middle East & Africa Asthma and COPD Drugs Market, by Country
      1. GCC Countries
        1. GCC Countries Asthma and COPD Drugs Market, By Diseases
          1. By Asthma
          2. By COPD
        2. GCC Countries Asthma and COPD Drugs Market, By Medication Class
          1. By Combination Drugs
          2. By Bronchodilators
          3. By Inhaled Corticosteroids (ICS)
          4. By Short Acting Beta Agonists (SABA)
          5. By Long Acting Beta Agonists (LABA)
          6. By Leukotriene Antagonists (LTA)
          7. By Anticholinergics
          8. By Anti-Inflammatories
          9. By Other Classes
        3. GCC Countries Asthma and COPD Drugs Market, By Distribution Channel
          1. By Retail Pharmacies
          2. By Hospital Pharmacies
          3. By Online Pharmacies
          4. By Drug Stores
      2. South Africa
        1. South Africa Asthma and COPD Drugs Market, By Diseases
          1. By Asthma
          2. By COPD
        2. South Africa Asthma and COPD Drugs Market, By Medication Class
          1. By Combination Drugs
          2. By Bronchodilators
          3. By Inhaled Corticosteroids (ICS)
          4. By Short Acting Beta Agonists (SABA)
          5. By Long Acting Beta Agonists (LABA)
          6. By Leukotriene Antagonists (LTA)
          7. By Anticholinergics
          8. By Anti-Inflammatories
          9. By Other Classes
        3. South Africa Asthma and COPD Drugs Market, By Distribution Channel
          1. By Retail Pharmacies
          2. By Hospital Pharmacies
          3. By Online Pharmacies
          4. By Drug Stores
      3. Rest of Middle East & Africa
        1. Rest of Middle East & Africa Asthma and COPD Drugs Market, By Diseases
          1. By Asthma
          2. By COPD
        2. Rest of Middle East & Africa Asthma and COPD Drugs Market, By Medication Class
          1. By Combination Drugs
          2. By Bronchodilators
          3. By Inhaled Corticosteroids (ICS)
          4. By Short Acting Beta Agonists (SABA)
          5. By Long Acting Beta Agonists (LABA)
          6. By Leukotriene Antagonists (LTA)
          7. By Anticholinergics
          8. By Anti-Inflammatories
          9. By Other Classes
        3. Rest of Middle East & Africa Asthma and COPD Drugs Market, By Distribution Channel
          1. By Retail Pharmacies
          2. By Hospital Pharmacies
          3. By Online Pharmacies
          4. By Drug Stores
  9. Key Market Dynamics
    1. Introduction
    2. Market Drivers
    3. Market Restraints
    4. Market Opportunities
    5. Porter's Five Forces Analysis
    6. PEST Analysis
    7. Regulatory Landscape
    8. Technology Landscape
    9. Regional Market Trends
  10. COVID 19 Impact Analysis
    1. Key strategies undertaken by companies to tackle COVID-19
    2. Short term dynamics
    3. Long term dynamics
  11. Marketing Stratagy Analysis
    1. Marketing Channel
    2. Direct Marketing
    3. Indirect Marketing
    4. Marketing Channel Development Trends
  12. Competative Landscape
    1. Competition Matrix - 2021
    2. Company Market Share Analysis - 2021
    3. Key Company Activities, 2018 - 2021
    4. Strategic Developments - Heat Map Analysis
    5. Company Offering Evaluation
    6. Company Regional Presence Evaluation
  13. Company Profiles
    1. Novartis AG (Switzerland)
    2. Cipla Inc. (India)
    3. Abbott Laboratories (U.S.)
    4. Astellas Pharma (Japan)
    5. Hoffmann-La Roche Ltd. (Switzerland)
    6. Glenmark Pharmaceuticals (India)
    7. Verona Pharma PLC (UK)
    8. AstraZeneca (UK)
    9. GSK (UK)
    10. Pfizer Inc. (U.S.)
    11. Teva Pharmaceutical Industries Ltd. (Israel)
    12. Merck & Co. Inc. (U.S.)
    13. Grifols S.A. (Spain)
  14. Key Primary Respondents - VERBATIM
  15. Discussion Guide
  16. Customization Offered
  17. Annexure
  18. List of Figures
  19. List of Tables
  20. List of Abbreviations
FAQ
Frequently Asked Question
  • The global Asthma and COPD Drugs valued at USD 37.42 Billion in 2023 and is expected to reach USD 57.56 Billion in 2032 growing at a CAGR of 4.9%.

  • The prominent players in the market are Novartis AG (Switzerland), Cipla Inc. (India), Abbott Laboratories (U.S.), Astellas Pharma (Japan), Hoffmann-La Roche Ltd. (Switzerland), Glenmark Pharmaceuticals (India), Verona Pharma PLC (UK), AstraZeneca (UK), GSK (UK), Pfizer Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Merck & Co. Inc. (U.S.), Grifols S.A. (Spain).

  • The market is project to grow at a CAGR of 4.9% between 2024 and 2032.

  • The driving factors of the Asthma and COPD Drugs include

    • The rising incidence of asthma and COPD globally is a significant driver for the market, primarily fueled by several interconnected factors

  • North America was the leading regional segment of the Asthma and COPD Drugs in 2023.